


Fig. 1

Control Compound I SLIGRL



BEST AVAILABLE COPY

Fig. 2


Control



Cpd.I



SLIGRL



BEST AVAILABLE COPY

Fig. 3

Control, STI, and SLIGRL


Control



STI




SLIGRL



BEST AVAILABLE COPY

Fig. 4A



BEST AVAILABLE COPY

Fig. 4B





Fig. 5A

Control



SLIGRL



STI



CpdI



BEST AVAILABLE COPY

Figure 5B



BEST AVAILABLE COPY

Fig. 6A

Control



SLIGRL



Cpdl



BEST AVAILABLE COPY

Fig. 6B





Fig. 7A

Control

SLIGRL



BEST AVAILABLE COPY

Fig. 7B


Control



SLIGRL

BEST AVAILABLE COPY

Fig. 7C



Control

STI

BEST AVAILABLE COPY

Figure 8






Figure 9



BEST AVAILABLE COPY

Figure 10

Control




Anti ICAM-1 antibody



BEST AVAILABLE COPY

FIG 11



BEST AVAILABLE COPY